This brand name is authorized in Canada, United States
The drug DUOBRII contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Ulobetasol
UNII 91A0K1TY3Z - HALOBETASOL PROPIONATE
|
|
Ulobetasol is a corticosteroid used for for the topical treatment of plaque psoriasis. Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown. |
|
2
Tazarotene
UNII 81BDR9Y8PS - TAZAROTENE
|
|
Tazarotene, a member of the acetylenic class of retinoids, is a prodrug which is converted to its active free form, tazarotenic acid, by de-esterification in the skin area. Tazarotenic acid is the only known metabolite of tazarotene to have retinoid activity. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| D05AX05 | Tazarotene | D Dermatologicals → D05 Antipsoriatics → D05A Antipsoriatics for topical use → D05AX Other antipsoriatics for topical use |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: CA | Health Products and Food Branch | Identifier(s): 02499967 |
| Country: US | FDA, National Drug Code | Identifier(s): 0187-0653 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
